Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

+ DOXIL to VELCADE monotherapy, the standard of care in patients with previously treated MM. Results were presented by Dr. Harousseau and showed:

    -- A survival advantage was observed for the VELCADE + DOXIL combination,

       after approximately 20 percent of events occurred (p<0.05, hazard

       ratio=1.406, 95 percent confidence interval [1.002; 1.972])

    -- Median time to progression (TTP) of 9.3 months for the combination, a

       43 percent, highly statistically significant reduction in risk of

       disease progression over the control arm (p<0.00001)

    -- A predictable safety profile consistent with the known toxicities of

       the two agents, including thrombocytopenia, neutropenia and anemia

The trial included 646 patients who had received at least one prior therapy. Patients were randomized in a one-to-one ratio, with 322 patients receiving VELCADE at 1.3 mg/m2 on days 1, 4, 8 and 11 of the 21-day cycle and 324 patients receiving the same dose and schedule of VELCADE with the addition of DOXIL at 30 mg/m2 given on day 4 of each cycle. Patients were treated for up to eight cycles. The primary endpoint of the study was TTP as defined by the interval between the date of randomization and the date of disease progression, including relapse after complete response or death due to disease progression. In both arms, 66 percent of patients had received more than two prior therapies before entering the trial. Responses were assessed by European Group for Blood and Marrow Transplantation (EBMT) criteria.

About Multiple Myeloma (MM)

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approxi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
Post Your Comments:
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/d85hx9/global_rapid ) has announced the addition ... - Applications and Technologies" report to their offering. ... estimated at US$19.4 billion in 2014, forecast at US$20.4 ... CAGR of 5.7% between 2014 and 2020 to reach ... global market for Rapid Medical Diagnostic Kits (MDKs) has ...
(Date:5/27/2015)... May 27, 2015 E-QURE, Corp. ... engaged in the development and commercialization of its Bio-electrical ... electrotherapy for the noninvasive treatment of hard to heal ... Zacks Small Cap Research http://scr.zacks.com issued a ... According to Zacks, research update, E-QURE Corp "…has a ...
(Date:5/27/2015)... LONDON , May 27, 2015 ... you trends, partnerships, and predicted revenues   ... manufacturing heading? What are the commercial prospects for ... a whole? Visiongain ,s new report shows you ... opportunities and prospects. Our 203 page report ...
Breaking Medicine Technology:Global Rapid Medical Diagnostic Kits Market - 2015-2020 Applications and Technologies Analysis of the $27 Billion Industry 2Global Rapid Medical Diagnostic Kits Market - 2015-2020 Applications and Technologies Analysis of the $27 Billion Industry 3Global Rapid Medical Diagnostic Kits Market - 2015-2020 Applications and Technologies Analysis of the $27 Billion Industry 4Zacks Investment Small Cap Research Issues Quarterly Update on E-QURE 2Zacks Investment Small Cap Research Issues Quarterly Update on E-QURE 3Medical Device Contract Manufacturing Market Forecast 2015-2025 2Medical Device Contract Manufacturing Market Forecast 2015-2025 3Medical Device Contract Manufacturing Market Forecast 2015-2025 4Medical Device Contract Manufacturing Market Forecast 2015-2025 5Medical Device Contract Manufacturing Market Forecast 2015-2025 6Medical Device Contract Manufacturing Market Forecast 2015-2025 7
... Mich., May 15, 2012  InfuSystem Holdings, Inc. (NYSE MKT: ... related services for the healthcare industry, today announced that ... on Monday, May 21, 2012 following the market close.  ... conference call on Tuesday, May 22, 2012 at 9:00 ...
... 15, 2012 /PRNewswire-iReach/ -- Global Information Inc. ... Drug Development: Contract Research Organizations Market ... at the rate of 12% from 2009 to 2010 ... Contract Research Organizations Market to 2018 : Public-Private Partnerships ...
Cached Medicine Technology:Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise 2
(Date:5/27/2015)... 2015 Genius Monkey is pleased to ... marketing technology, they have boosted sales for the Utah ... regional level for seven Utah-based dealers. , Until ... and radio media. In 2014 the Utah Honda dealers ... Genius Monkey , shifted their marketing campaigns more ...
(Date:5/27/2015)... May 27, 2015 “Heroin has never been ... our overdoses are coming from,” says Harford County Sheriff Jeff ... May 8th. In the surging heroin related incidents in Baltimore, ... prevention education to prevent heroin addiction and subsequent abuse before ... charge. Drug Rehab Baltimore is a drug and alcohol rehab ...
(Date:5/27/2015)... 2015 SmarterSkin, http://www.smarterskindermatology.com , is taking ... test that makes it easier for patients to find skin ... , Dr. Sejal Shah is a cosmetic dermatologist based in ... offer the test. This revolutionary DNA test uses 16 genetic ... aging: , 1. Firmness and elasticity , 2. ...
(Date:5/27/2015)... Holly CaSaroll, founder of FACE, the award-winning beauty ... cancer. The skin is the body’s largest organ and is ... 3.5 million cases of skin cancer are diagnosed in the ... sun's ultraviolet rays (UVR). , There are several things ... Avoid the sun between the hours of 10 AM and ...
(Date:5/27/2015)... May 27, 2015 The news is ... of lack of compliance documentation or appropriate training: an ... Miami, a propane gas company in Texas and the ... for incidents and accidents due to improper training and ... is proud to introduce the new Supervisor feature which ...
Breaking Medicine News(10 mins):Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2Health News:In Recognition of National Melanoma Awareness Month, Beauty Guru Details Skin Tips to Prevent Cancer and Premature Aging 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 3
... 28 (HealthDay News) -- Rheumatoid arthritis (RA) patients with low ... study finds. Previous research has shown that 13 percent ... associated with worse outcomes. In this new study, researchers ... 466 RA patients and found that 37 percent of them ...
... 28 (HealthDay News) -- Retired professional football players use ... the general U.S. population, a new study shows. ... 1979 and 2006 about their overall health, level of ... prescription pain drugs. Seven percent of the retired ...
... preserve the voice and vocal cord function for patients ... a study from Henry Ford Hospital in Detroit. ... squamous cell carcinomas, offering patients a less invasive option ... the voice," says study co-author Vanessa G. Schweitzer, FACS, ...
... Reporter , FRIDAY, Jan. 28 (HealthDay News) -- People facing ... by lack of control -- with doctors poking and prodding ... Hospice care, however, can give back some control over ... and helping both the dying person and the person,s family ...
... Australian researchers have come one step closer to understanding ... why many common drugs, including some antibiotics, antihistamines and ... It is estimated around 40-50% of all drugs in ... carries electricity in the heart and, as a result, ...
... Thompson HealthDay Reporter , FRIDAY, Jan. 28 (HealthDay News) ... doesn,t mean you die on anyone else,s timetable. Dennis, 91, ... ago, after she was diagnosed with a fatal heart condition. At ... "The illness, the heart condition that I have, is one ...
Cached Medicine News:Health News:Depression in Rheumatoid Arthritis Patients Linked to Social Status 2Health News:Retired NFL Players More Likely to Take Painkillers 2Health News:Voice-saver: Light therapy for early-stage laryngeal cancer 2Health News:Voice-saver: Light therapy for early-stage laryngeal cancer 3Health News:More People Choosing Hospice at Life's End 2Health News:More People Choosing Hospice at Life's End 3Health News:Victor Chang scientists unlock the 'gates' on sudden cardiac death 2Health News:Woman's Life Refutes a Hospice Myth 2
... First Stop absorbable collagen hemostat. FirstStop is ... handling and removal characteristics. It can easily ... fit the wound. FirstStop products are not ... peeled away after hemostasis is achieved. As ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
... D-Stat Flowable Hemostat has a thick, ... application, such as vascular access sites ... is also used as an adjunct ... tissue tracts of femoral access sites ...
The D-Stat Radial hemostat band utilizes a compression band together with the active haemostatic material of the D-Stat to control surface bleeding....
Medicine Products: